GSK receives FDA warning letter on regulatory reporting
The letter follows a routine FDA inspection of GlaxoSmithKline’s (GSK’s) reporting processes conducted last year. The observations from the inspection primarily relate to omissions from periodic reports to
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.